Transactions

Licensing Deals

XOMA

License of Global Rights to Anti-TGF-beta Antibody Program to Novartis

Up to $517 million

October 2015

North America

arGEN-X

License of a preclinical antibody to LEO Pharma

Up to €105 million

May 2015

Europe

Lightlake Therapeutics

License of naloxone opioid overdose reversal treatment to Adapt Pharma

>$55 million

December 2014

Europe

Aseptix Health Sciences

License of antimicrobial technology to Ecolab

December 2014

Europe

CureTech

License of pidilizumab to Medivation

Up to $335 million with royalty

October 2014

Asia, Africa, MidEast, Latin America

Almac

License to Chemotherapy Benefit Test for High Risk Breast Cancer

$9 million + milestones and royalties

November 2013

Europe

Undisclosed

Arrangement of Authorized Generic Marketer

September 2013

North America

Compugen

Advisor on oncology partnership with Bayer

$550mm with $10mm upfront

August 2013

Asia, Africa, MidEast, Latin America

Sofgen

Sale of Nimodipine ANDA to ANI Pharmaceuticals

August 2013

Europe

Merus Labs

Sale of Factive rights in North America to Okana Ventures

$3.4 mm + Equity

August 2013

North America

Clinigen

Acquisition of EU rights to Vibativ from Theravance

$5mm + royalties

March 2013

Europe

Undisclosed

License of Rights of an OTC Product to a Large Pharma

March 2013

Europe

SpePharm

Joint Venture with Norgine

December 2012

Europe

Undisclosed

Licensing transaction to a large pharma in the pain area

October 2011

Europe

Lpath

Advisor in iSonep License to Pfizer

$500mm with $14mm upfront

December 2010

North America

Columbia Labs

Columbia Prochieve License Watson

$92.5mm with $47 upfront

July 2010

North America

Undisclosed

License of antimicrobial product to global device company

January 2010

North America

Ikonisys

Marketing Agreement with ENZO Labs

December 2009

North America

Undisclosed

Advisor in the license to a cardiovascular product from a large pharma

December 2009

North America

Undisclosed

Advisor in license of novel vaccine to large pharma

> $500mm

December 2009

North America

Almac

Advisor on licensing and commercialization agreement with Genomic Health

Almac Group announced that Genomic Health will exclusively license Almac’s technology and intellectual property to further develop, validate, and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX® score. Genomic Health will identify a study cohort for the validation of Almac’s previously identified and published genes. Genomic Health made an up-front payment of $9 million dollars, which the company expects to expense in the fourth quarter of 2013, and will pay additional milestones as certain clinical and commercial endpoints are achieved in the future. Upon successful commercialization of the test, Genomic Health will pay additional royalties to Almac Group.

Press Release

Compugen

Advisor on oncologly partnership with Bayer

Compugen Ltd. signed a collaboration and license agreement with Bayer HealthCare for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the agreement Compugen will receive an upfront payment of $10 million, and is eligible to receive over $500 million in potential milestone payments for both programs, not including milestone payments of up to $30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.

Clinigen

Acquisition of ex-U.S. rights to Vibativ from Theravance

Clinigen acquired exclusive commercialization rights to VIBATIV® in the EU and certain other European countries (including Switzerland and Norway) from Theravance. In exchange, Theravance will receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV®, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen. VIBATIV® is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action. The drug is approved in the United States for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-Positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, since 2009. In 2011, the European Commission granted marketing authorization for VIBATIV® for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable.

Press Release

Lpath

Advisor in iSonep License to Pfizer

Lpath, developer of therapeutic antibodies, entered into an agreement with Pfizer. Lpath has provided Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEP, one of Lpath humanized monoclonal antibodies. Under the terms of the agreement, Pfizer will provide Lpath with an upfront option payment of $14 million in addition to sharing the cost of the planned Phase 1b and Phase 2a trials. Following completion of the two studies, Pfizer has the right to exercise its option for worldwide rights to iSONEP for an undisclosed option fee and, if Pfizer exercises its option, Lpath will be eligible to receive development, regulatory, and commercial milestone payments that could total up to $497.5 million. In addition, Lpath will be entitled to receive tiered double-digit royalties based on sales of iSONEP.

Press Release

Columbia Labs

Columbia Prochieve License Watson

Columbia Laboratories sold the rights to its bioadhesive progesterone gel product Prochieve to Watson Pharmaceuticals. Watson was looking to expand its Women's Health brand product portfolio. Under the terms of the agreement, Watson provided Columbia with an initial $47 million payment and received exclusive progesterone gel product rights in the U.S. and 11.2 million newly issued shares of Columbia common stock. The deal included additional contingent payments related to the successful completion of clinical development milestones, receipt of regulatory approvals and product launches for a total of approximately up to $45.5 million.

Press Release

Ikonisys

Marketing Agreement with ENZO Labs

Ikonisys entered a marketing partnership with Enzo Biochem to market Ikonisys' proprietary oncoFISH cervical test. Under the agreement, Enzo Clinical Labs will market the assay to physicians in the States of New York and New Jersey. Ikonisys will conduct the evaluation of the specimen using its proprietary technology.